<DOC>
	<DOCNO>NCT00479336</DOCNO>
	<brief_summary>To investigate dose response change baseline body weight primary endpoint investigate improvement ascites , abdominal circumference , lower-limb edema , pleural effusion secondary endpoint seven-day repeated oral administration OPC-41061 7.5 , 15 , 30 mg/day placebo cirrhosis patient ascites despite take conventional diuretic .</brief_summary>
	<brief_title>A Dose-defining Study OPC-41061 Treatment Hepatic Edema</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Subjects ascites despite take either follow combination loop diuretic antialdosterone agent ( spironolactone ) least 7 day prior start study drug administration . Combination 1 : Loop diuretic indicate combination antialdosterone agent daily dose 25 mg Furosemide : 40 mg/day Other loop diuretic : daily dosage equivalent 40 mg furosemide Bumetanide : 1 mg/day , Piretanide : 6 mg/day , Azosemide : 60 mg/day , Torasemide : 8 mg/day Combination 2 : Antialdosterone agent daily dose 50 mg combination furosemide daily dose 20 mg ( one loop diuretic specify Combination 1 daily dosage equivalent 20 mg furosemide ) 2 . Patients hospitalize able stay study site start runin observation period completion postdosing observation 2 . 3 . Subjects capable give informed consent participate study free . 1 . Subjects follow complication symptom : ( 1 ) Hepatic encephalopathy ( Hepatic coma grade : II ) , ( 2 ) Poorlycontrolled hepatocellular carcinoma ( i.e. , hepatocellular carcinoma vessel infiltration confirm image main trunk main branch portal vein , inferior vena cava , main trunk hepatic vein ) , ( 3 ) Endoscopic finding within 30 day prior screen examination require new therapy esophageal gastric varicose vein study period , ( 4 ) Repeated haemorrhoidal bleeding due rectal varicose vein within 30 day prior screen examination , ( 5 ) Diabetes mellitus poorly control blood glucose , ( 6 ) Heart failure ( NYHA class III IV ) , ( 7 ) Anuria , ( 8 ) Impairment urination due urinary tract stricture , urinary calculus , tumor urinary tract , cause 2 . Subjects history follow disease : ( 1 ) Cerebrovascular disorder within 30 day prior screen examination , ( 2 ) Episode gout within 90 day prior screen examination , ( 3 ) Hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride . 3 . Subjects obese ( body mass index [ BMI , body weight ( kg ) /height ( ) 2 ] exceed 35 ) 4 . Patients supine systolic blood pressure exceed 90 mmHg 5 . Subjects follow abnormal laboratory value : hemoglobin exceed 8.0 g/dL , total bilirubin exceed 3.0 mg/dL , serum creatinine exceed 3.0 mg/dL , serum sodium exceed 147 mEq/L , serum potassium exceed 5.5 mEq/L , uric acid exceed 8.0 mg/dL 6 . Patients unable take oral medication 7 . Female subject pregnant , possibly pregnant , lactate , plan become pregnant 8 . Subjects receive blood product , include albumin , within 7 day prior screen examination 9 . Subjects receive investigational drug OPC41061 within 30 day prior screen examination 10 . Subjects previously participate study OPC41061 receive OPC41061 11 . Subjects otherwise judge investigator subinvestigator inappropriate inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>OPC-41061</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>ascites</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>